ACADIA Pharmaceuticals (NASDAQ:ACAD) Insider Sells $114,393.18 in Stock

Key Points

• ACADIA Pharmaceuticals insider James Kihara sold shares on May 26, offloading 5,401 shares at an average price of $21.18 for a total of $114,393.18. The sale reduced his ownership by 18.06%.
• ACAD shares dipped slightly to $21.19, down 0.3% on the day, with trading volume below average. The stock currently has a market cap of $3.63 billion and is trading near its 52-week low of $19.69.
• Recent earnings came in below expectations, with ACADIA reporting $0.02 EPS versus the $0.04 consensus and revenue of $268.1 million versus $280.25 million expected. Despite the miss, analysts still largely rate the stock a Moderate Buy with a $31.63 average price target.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) insider James Kihara sold 5,401 shares of the company's stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total transaction of $114,393.18. Following the completion of the transaction, the insider owned 24,509 shares of the company's stock, valued at $519,100.62. This trade represents a 18.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

James Kihara also recently made the following trade(s):

• On Monday, May 4th, James Kihara sold 1,332 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $21.79, for a total value of $29,024.28.
• On Tuesday, April 7th, James Kihara sold 1,030 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $22.20, for a total value of $22,866.00.

ACADIA Pharmaceuticals Stock Down 0.3%

Shares of ACADIA Pharmaceuticals stock traded down $0.07 during trading on Wednesday, hitting $21.19. 982,349 shares of the stock traded hands, compared to its average volume of 1,702,755. The stock has a market cap of $3.63 billion, a price-to-earnings ratio of 9.63, a PEG ratio of 25.54 and a beta of 0.86. ACADIA Pharmaceuticals Inc. has a 52 week low of $19.69 and a 52 week high of $28.35. The firm's fifty day moving average is $21.70 and its 200-day moving average is $23.84.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.02). ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The firm had revenue of $268.10 million during the quarter, compared to the consensus estimate of $280.25 million. During the same quarter in the previous year, the firm earned $0.11 EPS. The business's quarterly revenue was up 9.7% compared to the same quarter last year. On average, analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.39 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ACAD has been the subject of a number of recent analyst reports. TD Cowen upped their target price on ACADIA Pharmaceuticals from $35.00 to $37.00 and gave the company a "buy" rating in a report on Thursday, February 26th. Mizuho raised shares of ACADIA Pharmaceuticals from a "neutral" rating to an "outperform" rating and boosted their price objective for the company from $29.00 to $35.00 in a research report on Monday, February 23rd. Royal Bank Of Canada decreased their price objective on shares of ACADIA Pharmaceuticals from $31.00 to $30.00 and set an "outperform" rating for the company in a report on Thursday, February 26th. Oppenheimer reaffirmed a "market perform" rating on shares of ACADIA Pharmaceuticals in a research report on Friday, February 6th. Finally, Citigroup cut their target price on shares of ACADIA Pharmaceuticals from $33.00 to $32.00 and set a "buy" rating on the stock in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, ACADIA Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $31.63.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ACAD. State Street Corp raised its position in shares of ACADIA Pharmaceuticals by 9.0% in the 4th quarter. State Street Corp now owns 7,910,733 shares of the biopharmaceutical company's stock worth $211,296,000 after purchasing an additional 655,257 shares during the last quarter. First Trust Advisors LP grew its position in ACADIA Pharmaceuticals by 47.3% during the 1st quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company's stock valued at $74,435,000 after purchasing an additional 1,073,834 shares during the last quarter. Geode Capital Management LLC increased its stake in ACADIA Pharmaceuticals by 3.4% during the 4th quarter. Geode Capital Management LLC now owns 3,239,451 shares of the biopharmaceutical company's stock valued at $86,539,000 after purchasing an additional 106,807 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in ACADIA Pharmaceuticals by 8.0% in the first quarter. Dimensional Fund Advisors LP now owns 3,155,160 shares of the biopharmaceutical company's stock worth $70,222,000 after buying an additional 234,186 shares during the last quarter. Finally, Braidwell LP purchased a new position in ACADIA Pharmaceuticals in the third quarter worth about $50,760,000. 96.71% of the stock is owned by hedge funds and other institutional investors.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company's flagship product, NUPLAZID® (pimavanserin), received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.